Haihe Biopharma News and Activities
Presence
Haihe Biopharma is a biotechnology company focused on the discovery, development, and commercialization of innovative drugs for cancer treatment. Their products target a range of oncological conditions, aiming to meet the advancing needs in global cancer care.
- Oncology drugs
- Clinical development services
Employees: 500
Haihe Biopharma is one of the...
Executives
View the org chart displaying its 9 main executives
Most searched biographies at Haihe Biopharma
- Ruiping Dong, Chief Executive Officer
- Jian Ding, Chairman of the Board
- Catherine Gu, Executive Marketing Director
Create your alert
to follow the executive moves at Haihe Biopharma.
Biotechnology
Haihe Biopharma has 2,340 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and Biogen (United States (USA)).
Popular M&A news in Biotechnology
- Regeneron Pharmaceuticals has announced the acquisition of 23andMe (posted on May 20 2025).
- Stylus Medicine has just announced a $85 Million fundraising (posted on May 16 2025).
- Azafaros has just announced a $132 Million fundraising (posted on May 15 2025).
Popular contacts in Biotechnology
News
Press releases by Haihe Biopharma
- Haihe Biopharma Announces that Paclitaxel Oral Solution (RMX3001) was Approved by NMPA as Second-line Treatment for Gastric Cancer
- Haihe Biopharma and Taiho Pharmaceutical Announce the Launch of MET Inhibitor HAIYITAN® Tablets 50mg in Japan
- Haihe Announces First Patient Treated in China in SCC244-G303 Phase III Trial
- An innovative drug Gumarontinib (MET inhibitor) discovered and developed by Haihe Biopharma has been successfully approved in Japan
- Haihe Biopharma Presented results of two clinical studies in 2024 ASCO Annual Meeting
- Haihe Biopharma Announces Preliminary Results from the Phase 1 Part of a First-in-Human Phase I/II Study of EZH1/2 Inhibitor HH2853 in the Epithelioid Sarcoma Population at ASCO Annual Meeting 2023
- Haihe Biopharma Announces Preliminary Results of the First-in-Human Clinical Study of EZH1/2 Inhibitor HH2853 at AACR Annual Meeting 2023
- Haihe Biopharma Announces the Clinical Results of Gumarontinib (INN) in The eClinicalMedicine
- Haihe Biopharma are presenting two drug discovery projects in 2024 AACR Annual Meeting
- View more press releases Close
Social media about Haihe Biopharma
- Haihe Biopharma on Wikipedia, Google News & Yahoo Finance
- Haihe Biopharma on LinkedIn, Twitter & YouTube
